Drug Retail

JZJ released FY2026 Q1 earnings on April 27 Pre-Market (BJT), actual revenue CNY 2.091 B, actual EPS CNY 0.24

JZJ FY2026 Q1 Earning Release on April 28 Pre-Market BJT

JZJ to Release FY2025 Earnings on April 28 Pre-Market (BJT), Forecast Revenue CNY 13.06 B, EPS CNY 3.6166

JZJ released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 2.092 B, actual EPS CNY 0.1805

JZJ released FY2025 9 Months Earnings on October 29 Pre-Market (BJT), actual revenue CNY 6.549 B, actual EPS CNY 0.6502

JZJ FY2025 Q3 Earnings Release on October 30, Pre-Market BJT

JZJ released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 2.162 B, actual EPS CNY 0.2496

JZJ released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue CNY 4.457 B, actual EPS CNY 0.47

JZJ to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Lan Xinyue Plans Continued Share 增持 of Jianzhijia

Jianzhijia's Controlling Shareholder Increases Shareholding Ratio

Jianzhiya's Q1 2025 Net Profit Declines 35.85%

JZJ released FY2024 annual earnings on April 28 Pre-Market BJT, actual revenue CNY 9.283 B (forecast CNY 10.77 B), actual EPS CNY 0.83 (forecast CNY 2.975)

JZJ released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 2.294 B, actual EPS CNY 0.22

JZJ released FY2024 Q4 earnings on April 28 Pre-Market (BJT), actual revenue CNY 2.548 B, actual EPS CNY 0.1794

JZJ FY2025 Q1 Earnings Release Scheduled for April 29, After-Market BJT

JZJ to release FY2024 earnings report on April 29 Pre-Market (BJT), forecast revenue CNY 10.77 B, EPS CNY 2.975

Jianzhijia Assesses the Impact of US Tariffs and China's Countermeasures on the Company

Jianzhijia's Net Profit Expected to Decrease Significantly by 68.78% to 65.50% in 2024

Jianzhijia Obtains 70 Million Yuan Stock Repurchase Special Loan from China Construction Bank

01833

510660

589720

603939

603883

605266

159929

002727

36Kr learned that recently, after Ping An Good Doctor reached deep cooperation with two major listed chain pharmacies, LBX and Yifeng, the "Ping An Circle" offline service network has achieved significant implementation in the southwest market: "Ping An Circle" successfully signed deep cooperation agreements with three regional chains, YIXINTANG, JZJ, and Guizhou Yishu

36Kr

PA GOODDOCTOR

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

Yifeng Pharmacy

China Universal 800 Health Care ETF

YIXINTANG

The "Ping An Circle" has signed a deep cooperation agreement with YIXINTANG, JZJ, and Guizhou Yishu, three major regional chains

603233

CITIC Construction Investment released a research report indicating that the pharmacy industry is experiencing a mild recovery, while traditional pharmacies face development pain points, making differentiated transformation imperative. The industry needs to adapt to the economic environment, policy changes, and consumer habits, differentiating into specialized and diversified pharmacies. Specialized pharmacies meet the needs of patients discharged from hospitals, while diversified pharmacies focus on daily health needs. Compared to Japan, pharmacy companies need to leverage policy support to promote differentiated development in order to gain additional growth

Zhitong

CITIC Construction Investment: The pharmacy industry is currently recovering moderately, and transformation is expected to catalyze valuation enhancement

JZJ announced that the shareholding ratio of the actual controllers, Mr. Lan Bo and Ms. Shu Chang, has increased from 40.6787% to 40.7056%. This change in equity is due to the appointment of senior management by three partnership enterprises, resulting in the executives and the partnership enterprises being deemed as acting in concert, forming a concerted action relationship with the actual controllers, leading to a total increase in shareholding ratio of 0.0269%. This change does not trigger a tender offer and will not result in a change in the actual controllers and controlling shareholders of the company

JZJ: The shareholding ratio of the actual controller and controlling shareholder has increased to 40.7056%

301017

China Post Securities released a research report indicating that the retail pharmacy industry is accelerating its clearance, with the number of closed pharmacies reaching 39,228 in 2024. It is expected that after industry consolidation, leading pharmacies will see a recovery in customer traffic. Leading pharmacies, leveraging their first-mover advantage in outpatient management, will attract more customers, enhance medical insurance consumption and related product consumption, thereby increasing the average transaction value and performance. Policy-driven prescription outflow and the trend of incorporating retail pharmacies into medical insurance management will further promote industry development

SYPM

China Post Securities: The retail pharmacy industry continues to clear out, and the ongoing coordination is expected to bring performance growth

300937

301408

Pharmaceutical commercial stocks opened strong, with YIXINTANG hitting the limit up, Hezong Medicine Easy-To-Buy Pharmaceutical rising over 10%, and JZJ, Saili Medical, Huaren Health, SYPM, and others following suit

Wallstreetcn

Hezong Medicine Easy-To-Buy Pharmaceutical

Huaren Health

Thalys

603299

603456

002766

688028

On April 29th, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 6.016 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Type of Restricted Shares Number of Shares Unlocked Jiuzhou Pharma 603456 Equity Incentive Restricted Circulation 480,900 Soling 002766 Equity Incentive Restricted Circulation 3.31 million JiangSu Suyan Jingshen 603299 Equity Incentive Restricted Circulation 3.3273 million Xiang Oil Pump 603319 Equity Incentive Restricted Circulation 326,900 JZJ 605266 Additional A Shares Legal Person Allocation Listed 11.5152 million WanNeng RiXin 301162 Pre-issuance Shares Restricted Circulation 35.4344 million Yongtaiyun 001228 Pre-issuance Shares Restricted Circulation 49 million Worldia 688028 7.5767 million Delong Laser 688170 23.74 million Jingye Intelligent 688290 41.36 million

JiangSu Suyan Jingshen

Jiuzhou Pharma

soling

Worldia

Delphi Laser

SPRIXIN

MHIM

BOOMY

Zhitong A-share lock-up release overview | April 29

JZJ announced that in the first quarter of 2025, the operating revenue was 2.294 billion yuan, a year-on-year decrease of 0.85%. The net profit attributable to shareholders of the listed company was 33.5256 million yuan, a year-on-year decrease of 35.85%. The basic earnings per share were 0.22 yuan/share, a year-on-year decrease of 35.29%

JZJ: Net profit in the first quarter of 2025 decreased by 35.85% year-on-year

603716

The three major stock indices closed slightly lower, with the Shanghai Composite Index at 3366.16 points, down 0.19%; the Shenzhen Component Index at 10825.70 points, down 0.17%; and the ChiNext Index at 2199.88 points, down 0.25%. The pharmaceutical commercial concept was active against the trend, with JZJ and Thalys hitting the daily limit. The cultivated diamond sector continued to be strong, with InnoLaser hitting the daily limit. The photovoltaic concept rose, with Haiyou New Materials hitting the daily limit. The multimodal AI concept and AI corpus concept collectively adjusted, with more stocks rising than falling, and over 3,300 stocks increased

Sinomach-pi

RJGF

HUATIE

Huawei

INNO LASER

HIUV

PCI-TGCL

HHWW

Closing Review: Three major stock indices slightly declined, and the pharmaceutical commercial concept remained active

000078

600829

The AI medical concept continues to strengthen, driving the pharmaceutical commercial sector to be active in the afternoon. LBX reached the daily limit, while NEPTUNUS, JZJ, HRPC, SYPM, and Yifeng Pharmacy saw significant gains

NEPTUNUS

HRPC

The pharmaceutical commercial sector is active against the trend, LBX hits the daily limit in the afternoon

According to the Zhitong Finance APP, JZJ announced that the share repurchase will expire on January 29, 2025. As of the announcement date, the company has actually repurchased a total of 4.3382 million shares through centralized bidding on the Shanghai Stock Exchange, accounting for 2.77% of the company's current total shares. The repurchase price ranged from 20.69 to 27.36 yuan per share, with a total amount of funds used being 94.9581 million yuan

JZJ spent CNY 94.9581 million to complete the repurchase of 2.77% of its shares

JZJ(605266.SH)